Comparative Pharmacology
Head-to-head clinical analysis: DYANAVEL XR versus QUILLICHEW ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYANAVEL XR versus QUILLICHEW ER.
DYANAVEL XR vs QUILLICHEW ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dyanavel XR is a central nervous system stimulant that increases the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and increasing their release, thereby enhancing neurotransmission in the brain regions involved in attention and impulse control.
Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.
Initial dose: 5 mg orally once daily in the morning. Maximum dose: 20 mg once daily. May increase by 5–10 mg weekly based on tolerability and response.
Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).
None Documented
None Documented
Mean terminal elimination half-life is approximately 8-10 hours for d-amphetamine and 12-14 hours for l-amphetamine; the extended-release formulation maintains therapeutic concentrations for 12-14 hours.
The terminal elimination half-life of methylphenidate is approximately 3-4 hours in children and 3.5-5 hours in adults. For QuilliChew ER, the extended-release formulation provides a prolonged absorption phase, with an effective duration of action of up to 12 hours.
Approximately 30-50% of a dose is excreted unchanged in urine; remainder as metabolites (primarily hippuric acid) via renal elimination. Fecal excretion is minimal.
QuilliChew ER (methylphenidate extended-release chewable tablet) is primarily eliminated via renal excretion as metabolites (60-80%) and unchanged drug (approx. 10%). Hepatic metabolism accounts for the remainder. Fecal elimination is minimal.
Category C
Category C
CNS Stimulant
CNS Stimulant